Table 1.
Correlation of Mul1 expression with clinicopathological characteristics in patients with ccRCC (TMA)
| Clinical features | TMA | ||
|---|---|---|---|
| Case | Mean ± SD | P‐value | |
| Tissue | |||
| Cancer | 100 | 0.91 ± 0.75 | .000** |
| Normal | 50 | 2.78 ± 0.91 | |
| Age (y) | |||
| <60 | 84 | 1.45 ± 1.14 | .352 |
| ≥60 | 66 | 1.64 ± 1.26 | |
| Gender | |||
| Male | 102 | 1.56 ± 1.17 | .705 |
| Female | 48 | 1.48 ± 1.25 | |
| Pathological grade | |||
| G1 | 66 | 0.88 ± 0.75 | .941 |
| G2‐G3 | 30 | 0.87 ± 0.73 | |
| Clinical stage | |||
| I | 62 | 1.16 ± 0.73 | .000** |
| II | 38 | 0.50 ± 0.60 | |
| Tumor invasion | |||
| T1 | 62 | 1.16 ± 0.73 | .000** |
| T2 | 38 | 0.50 ± 0.60 | |
| Lymph node metastasis | |||
| N0 | 100 | 0.91 ± 0.75 | — |
| N1 | 0 | — | |
| Distant metastasis | |||
| M0 | 100 | 0.91 ± 0.75 | — |
| M1 | 0 | — | |
Abbreviation: ccRCC, clear cell renal cell carcinoma; Mul1, mitochondrial E3 ubiquitin ligase 1; TMA, tissue microarray.
*P < .05; **P < .01.
"—" mean：data cannot be analyzed.